Search Results
Your search for all items matches 34705 pages
Showing 12451 - 12500COVID-19 Evidence Accelerator Leverages Real-World Data
The Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA) in collaboration with Friends of Cancer Research recently announced the COVID-19 Evidence Accelerator, an expansive public-private partnership combining the efforts of academic, government, and private sector organizations...
Paul G. Marks, MD, Visionary Leader of Memorial Sloan Kettering Cancer Center, Dies at 93
In 1980, Paul G. Marks, MD, became the President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK), the oldest and largest private cancer center in the world. Over his 19-year reign, he is credited with setting MSK on a more scientific course by encouraging innovative...
Researcher and Leader in Cancer Center Administration, John W. Yarbro, MD, PhD, Dies at 88
Most who leave a mark in life are noted for a single contribution; few are remembered for the breadth of their contributions. Such a man was John W. Yarbro, MD, PhD, who, near the end of his rich life, stepped foot on Antarctica, completing his desire to have visited all of the world’s seven...
Champion in Geriatric Oncology, Rosemary Yancik, PhD, Dies at 86
Rosemary Yancik, PhD, a medical sociologist, was best known for her talent of bringing a group of experts together who shared her interests in improving the prevention and management of cancer in elderly patients. She served many years at the National Institutes of Health in both the National...
What Have I Learned in More Than Half a Century in Cancer Medicine?
My journey in cancer medicine started in June 1968, when I traveled from Lebanon to New York to begin my fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Since then, and on a daily basis, I have been actively engaged in the treatment of patients with cancer and in cancer...
The Story of Three Patients With Leukemia
The human drama within the oncology world is a never-ending story of triumph, tragedy, and all of the valiant efforts and human emotions in between. The doctor-patient relationship in oncology is deeper and longer than in most medical specialties due to the life-and-death stakes at play after a...
Ancestry and Molecular Makeup of Cancer Evaluated in New Study
A new study by researchers from the National Cancer Institute (NCI) Cancer Genome Analysis Network, a collaborative group with investigators in the United States, Canada and Europe, provides the most comprehensive look to date at the effect of ancestry on the molecular makeup of normal and...
Artificial Blood Substitute
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Radium Era: 1916–1945 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Gynecologic Oncologist Describes His New Normal in a New York Hospital
During the COVID-19 pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Alexander Melamed, MD, MPH, a gynecologic oncologist and Assistant Professor of Obstetrics & Gynecology at NewYork-Presbyterian/Columbia...
NIH Begins Clinical Trial of Combination Regimen to Treat COVID-19
A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from COVID-19. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health...
Indiana University Researcher Receives $1.6 Million NCI Grant for Multiple Myeloma
G. David Roodman, MD, PhD, of Indiana University (IU) Melvin and Bren Simon Comprehensive Cancer Center, has been awarded a 5-year, $1.6 million grant from the National Cancer Institute (NCI) to study ways to build bone and decrease tumor growth in multiple myeloma bone disease. Dr. Roodman is...
American Academy of Arts & Sciences Inducts Members of Class of 2020
The American Academy of Arts & Sciences recently announced its newest members, with the election of 276 artists, scholars, scientists, and leaders in the public, nonprofit, and private sectors. Among those inducted were numerous researchers and scientists involved in the care of patients with...
Sleeping Well After Cancer: Patient-Centered Research for Treatment of Insomnia
Insomnia is a persistent sleep disorder that affects nearly 60% of people with cancer, diminishing their quality of life.1,2 Chronic insomnia disorder is defined by trouble falling asleep, staying asleep, or waking too early three times per week for 3 months or more.3 Standard care comprises...
Novel Imaging Application Illuminates Processes in Cancer, COVID-19
Medical images for a wide range of diseases, including COVID-19, can now be more easily viewed, compared, and analyzed using a Web-based imaging platform developed by Massachusetts General Hospital and collaborating researchers. The Open Health Imaging Foundation (OHIF) Web viewer was originally...
Is Estrogen Protective Against COVID-19?
Reports suggest that the severity of coronavirus infection may be significantly more pronounced in men than in women.1 Studies have demonstrated that estrogen reduces both influenza virus replication in human female nasal epithelial cells2 and moderates the cytokine storm in murine models of this...
Roswell Park Investigators Study Immunotherapy Combination in Patients With Cancer Infected With COVID-19
A clinical trial investigating a two-drug immunotherapy combination will soon be available to patients with cancer infected with COVID-19 at Roswell Park Comprehensive Cancer Center in Buffalo. The U.S. Food and Drug Administration (FDA) has authorized clinical researchers at the center to conduct...
Treating Patients With Leukemia During the COVID-19 Era at MD Anderson Cancer Center
As part of a series of interviews with cancer experts during the COVID-19 pandemic, The ASCO Post spoke with Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, about the impact of the pandemic on treatment of...
ECOG-ACRIN Conducts Smoking Cessation Study in Patients With Cancer
During the outbreak of the coronavirus disease, patients with cancer are at high risk of severe respiratory illness from infection because cancer and its treatments weaken their immune systems. Patients who smoke may be even more immunocompromised and at greater risk of COVID-19. A research study...
NIH Aims to Quantify Undetected Cases of Coronavirus Infection
A new study has begun recruiting at the National Institutes of Health (NIH) in Bethesda, Maryland, to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes COVID-19, have antibodies to the virus. The presence of antibodies in...
OneOncology Names Jeff Patton, MD, Chief Executive Officer
Jeff Patton, MD, has been named Chief Executive Officer of OneOncology, a national partnership of independent community oncologists. Dr. Patton has been Acting Chief Executive Officer and President of Physician Services since February. Dr. Patton will continue as Executive Chairman of the Board of ...
Melanoma Research Alliance Announces $11 Million for Grant Awards
In recognition of Melanoma Awareness Month, the Melanoma Research Alliance has announced funding for 26 research awards, totaling $10.9 million. These grant awards are made possible through the significant contributions of individuals, families, institutions, and corporate allies. The 26 awards...
Robert Bona, MD, Named Director of Benign Hematology Program at Yale Cancer Center Smilow Cancer Hospital
Yale Cancer Center has announced the appointment of Robert Bona, MD, as Professor of Medicine (Hematology) and inaugural Director of the Benign Hematology Program at Smilow Cancer Hospital. He will also join as Medical Director of the Hemophilia Treatment Center for the Pediatric Hematology &...
Despites Advances, Treatment-Related Sequelae Remain Problematic in Pediatric Neuro-oncology
The management of pediatric brain and spinal cord tumors is extremely complex, as are the survivorship issues in this highly vulnerable patient population. To shed light on the current clinical reality in this setting, The ASCO Post recently spoke with Katherine E. Warren, MD, an internationally...
Being Interviewed on Zoom? Here Are Some Professional Tips
You’ve agreed to be interviewed on Zoom. If you’re like most people, the technology itself isn’t a barrier. (And if it is, you can consult our step-by-step guide to using Zoom at https://bit.ly/2yxcTN0.) However, you might be less sure about what you can do to make the best impression (and the most ...
Martin F. Dietrich, MD, PhD, Joins Florida Cancer Institute
Florida Cancer Specialists & Research Institute of Lake Mary, Florida has announced that medical oncologist Martin F. Dietrich, MD, PhD, has joined the cancer specialty group. Dr. Dietrich is Board-certified in internal medicine and medical oncology. In his clinical practice, he addresses all...
Moffitt Appoints John Cleveland, PhD, as New Director
The Moffitt Cancer Center has announced the appointment of John Cleveland, PhD, as Center Director and Executive Vice President of the Tampa-based, National Cancer Institute (NCI)-designated comprehensive cancer center. Dr. Cleveland joined Moffitt in 2014 as Associate Center Director of Basic...
How California Dreamer John Craig Venter, PhD, Changed Paths to Focus on Sequencing the Human Genome
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with John Craig Venter, PhD, Founder, Chairman, and Chief Executive Officer of the J. Craig Venter Institute, a nonprofit organization dedicated to human, microbial, and environmental genomic research. A...
How the COVID-19 Pandemic Is Propelling the Delivery of Home Care for Patients With Cancer
In 2019, the Penn Center for Cancer Care Innovation at the University of Pennsylvania’s Abramson Cancer Center began planning a demonstration program, called Cancer Care at Home, to broaden the delivery of oncology treatments to patients in the home setting. The existing services offered by Penn...
Yale Cancer Center Announces Hematology Leadership Appointments
The Yale Cancer Center has announced the appointments of Thomas Prebet, MD, PhD, as Disease Aligned Research Team (DART) Leader for Myeloid Malignancies and Amer Zeidan, MBBS, as Director of the Hematology Early Therapeutics Program. In these new roles, Drs. Prebet and Zeidan will work closely with ...
Tucatinib in Previously Treated HER2-Positive Metastatic Breast Cancer
On April 17, 2020, tucatinib was approved for use in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. These patients included those with brain metastases and those who have received one or more prior...
Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer
On April 15, 2020, mitomycin gel was approved for the treatment of adult patients with low-grade upper tract urothelial cancer.1,2 Mitomycin gel is for pyelocalyceal use alone and not for intravenous, topical, or oral administration. Supporting Efficacy Data Approval was based on findings in the...
Genetics May Soon Guide Targeted Treatment of Brain Metastases
Genetic mapping of brain metastases, in the laboratory of Priscilla Brastianos, MD, Director of the Central Nervous System Metastasis Center at Massachusetts General Hospital/Harvard Medical School, and Scott Carter, PhD, at the Harvard School of Public Health, is yielding findings that could...
Luspatercept-aamt for Anemia in Adults With Myelodysplastic Syndromes
On April 3, 2020, luspatercept-aamt was approved in the treatment of anemia failing to respond to an erythropoiesis-stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks.1,2 The treatment is geared toward adult patients with very low– to intermediate-risk myelodysplastic ...
Selumetinib for Pediatric Neurofibromatosis Type 1 With Symptomatic, Inoperable Plexiform Neurofibromas
On April 10, 2020, the oral MEK inhibitor selumetinib was approved for the treatment of patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.1,2 Selumetinib is the first therapy approved for children who have this disease....
City of Hope Welcomes Stanley Hamilton, MD, and Alexey Danilov, MD, PhD
City of Hope has announced the addition of pathologist Stanley Hamilton, MD, and researcher Alexey Danilov, MD, PhD, to the National Medical Center in Duarte, California. Dr. Hamilton is a recognized leader in pathology who helped develop pathology and laboratory medicine into a world-class...
Breast Surgeon Eric A. Brown, MD, FACS, Joins Staff at Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute recently announced that breast surgeon Eric A. Brown, MD, FACS, has joined its medical team. Board-certified in general surgery and breast ultrasound, Dr. Brown will serve as co-leader of the Breast Cancer Multidisciplinary Team, alongside Michael Simon,...
ASCO’s President-Elect Aims to Ensure Equitable Cancer Care for Every Patient
The desire to pursue a career in medicine took root when Lori J. Pierce, MD, FASTRO, FASCO, was a young child visiting family in segregated Ahoskie, North Carolina. She witnessed firsthand the impact the town’s lone African American family physician had on the community. When it came time to...
Pemigatinib for Previously Treated Cholangiocarcinoma With FGFR2 Rearrangement or Fusion
On April 17, 2020, pemigatinib was granted accelerated approval for the treatment of adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by a U.S. Food and Drug...
AACR Virtual Annual Meeting I Draws Over 61,000 Registrants
The American Association for Cancer Research (AACR) announced that its first-ever Virtual Annual Meeting attracted a vast worldwide audience, with more than 61,000 registrants from 140 countries. Held April 27 and 28, the 2-day meeting featured practice-changing clinical trials, innovative basic...
Evolving Insights Into COVID-19 and Cancer Care
Pulling together the 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting in less than 1 month was a Herculean task, and an important component was producing a session on COVID-19 and cancer care. This special session involved researchers from the front lines of the pandemic...
Expert Point of View: Thomas J. Herzog, MD
Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PRIMA trial data along with updated results of the phase III PAOLA-1 trial of olaparib plus bevacizumab maintenance, called the data “practice-changing.” “We’ve suspected for a while...
Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancers
Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three PARP inhibitors at the European Society for Medical Oncology (ESMO) 2019 Congress.1 The picture became a little clearer on April 29, 2020, however,...
Expert Point of View: Shannon N. Westin, MD, MPH, FACOG and Alexander Melamed, MD, MPH
Discussant of the abstract on the WEE1 inhibitor adavosertib, Shannon N. Westin, MD, MPH, FACOG, Associate Professor and clinical investigator at The University of Texas MD Anderson Cancer Center, called the interaction between P53 and WEE1 an “opportunity for synthetic lethality.” She continued:...
Expert Point of View: Pamela N. Munster, MD
Formal I-SPY 2 trial discussant, Pamela N. Munster, MD, Professor in the Department of Medicine, University of California, San Francisco, found the study promising but said confirmatory trials are needed. “What we know so far in preoperative therapy for breast cancer is that pathologic complete...
WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma
Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series. The initial ...
Overcoming the Challenges of Presenting the ASCO Annual Meeting During the COVID-19 Pandemic
As the worldwide cases of the coronavirus started to mount in February and March, medical societies and organizations monitoring the escalating COVID-19 pandemic and its impact on international and domestic travel made the difficult decision to postpone or cancel their scientific conferences. On...
United Against Cancer to Accelerate Progress for Patients
When I chose my Presidential theme for the 2020 ASCO Annual Meeting, “Unite and Conquer: Accelerating Progress Together,” in early 2019, I never imagined it would take on a new meaning 12 months later. The world is grappling with the COVID-19 pandemic, and, even as we practice social distancing, I...
Metastatic Urothelial Cancer: A Conversation on State-of-the-Art Treatment Before the ASCO20 Virtual Scientific Program
As Thomas Powles, MD, PhD, of Queen Mary University of London, prepares to deliver his late-breaking presentation at the ASCO20 Virtual Scientific Program (LBA-1), he talks with Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, about current therapy: PD1/PDL1 inhibition in second-line...
ASTRO Survey Finds Fewer Patients Visiting Radiation Oncology Clinics, Despite Enhanced COVID-19 Safety Measures
Despite facing challenges such as limited access to personal protective equipment (PPE) following the COVID-19 outbreak, radiation oncology clinics quickly implemented safety and process enhancements that allowed them to continue caring for patients, according to a new national survey conducted by...
Prevalence of Endosalpingiosis and Association With Ovarian Cancer
Over the last decade, researchers have become concerned about a possible link between a benign gynecologic lesion called endosalpingiosis and ovarian cancer. However, using a diagnostic method typically reserved for specimens suspected of being cancerous, a team has found the prevalence of...
